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Sary This study aimed to determine the expession of Nm23-H1 in colorectal cancer and lver meta-
stases and to correlate N1m23-HI expression with dinicopathological variabe Simens from 59 primary
colorctal camns and five liver metastases were studied usin Northern blot hybriTisauion. The mean ± sc. of
tumour/normal (I/N) ratio of Nm23-H1 RNA expreson was 4.3 ± 0.4 (P<0.001) and 5.1 ± 0.90 (P<0.01)
for co_oectal cancer and iver tsases rI ty. No significant relationship was observed b n the
klv of Nm23-Hl RNA and the patent's age, scx, tumour location, differntiation, prmnce of lymph node
involvement or distant metatases Nm23-H1 RNA kvel was 2.6 ± 0.5 for tumour size less than 3.0 an and
4.6 ± 0.5 for those > 3.0 an (P = 0.05). Ther a ed to be a trend between ireasg lative Nm23-Hl
RNA and bowel wal invasi, ispec ofmetastatic status (Ti = 1.9 ± 0.3, T2 = 4.1 0.6, T3 = 4.1 ± 0.5
and T4 = 6.4 ± 1.6). Ths differe was statisically significant wen TI was against T 12 lesions
(P= 0.01). Western blot anabsis reveals two Nm23H-1 bands (17.0 kDa and 18.5kDa). In 16 cokorctal
patients, the T/N foldincreae in proten exps was 266 ± 0.46 (P<0.O01) and 240 0.32 (P<0.001)
for the 17.0 and 18.5 kDa band respctively. Both Nm23-HI RNA and protein kvs in primary colotl
canus do not appar to correlate with synchronous reg or distant metasases Since Nm23-HI RNA
expession is td with ineasing tumour size and tumour invason, Nm23-H1 RNA expresswion
may be assoated with local d on.
Nm 23, a putative tumour metastasis-suppressor gene, was
originally identified by differential hybridisation of K-1735
melanoma cell line clones of varying metastatic potential
(Steeg et al., 1988a). A tumour metastases-suppressor func-
tion was implicated by the reduced expression of Nm23 in
highly metastatic sublines compared with non-metastatic sub-
lines derived from the same K-1735 clone (Steeg et al.,
1988a,b; Rosengard et al., 1989, Leone et al., 1991). Further-
more, transfection of Nm23-HI cDNA into highly metastatic
K-1735 melanoma cell lines reduced their metastatic poten-
tial, independent of growth rate (Leone et al., 1991).
Thus far, a murine pNM23-Hl (Steeg et al., 1988a) and
human pNM23-HI (Rosengard et al., 1989) Nm23 cDNA
clones have been characterised. Both encode for a Mr 17,000
nuclear and cytoplasmic protein containing 152 amino acids
(Leone et al., 1991). The gene is located on chromosome
17q22 (Varesco et al., 1992). A second human gene, Nm23-
H2, was identified and shown to encode a protein with 88%
identity to the product of Nm23-H1 (Stahl et al., 1991), and
to be located in the same chromosomal region as Nm23-H1
(Backer et al., 1993). These genes share a high degree of
homology with the awd developmental gene in Drosophila
(Rosengard et al., 1989) and the nudeoside diphosphate
(NDP) kinase gene in Dictyosteliun (Wallet et al., 1990). The
Nm23-HI and Nm23-H2 genes have been shown to be iden-
tical to the human NDP kinase A and B chains respectively
(Gilles et al., 1991).
Several studies (Belivacqua et al., 1989; Barnes et al., 1991;
Hennessey et al., 1991; Hirayama et al., 1991; Royds et al.,
1993) have emphasised the clinical signi of Nm23 ex-
pression by demonstrating an increase in breast cancer
metastatic potential in tumours with decreased Nm23 expres-
sion. However, one study (Sastre-Garau et at., 1992) has
failed to show any relationship between breast cancer Nm23
expression and the presence of lymph node metastases. In
addition, although reduced Nm23 expression is associated
with early onset of melanoma metastases (Florenes et al.,
1992) and the presence of hepatoceliular carcinoma metas-
tases (Nakayama et al., 1992), incresed Nm23 expression
has been associated with a decrease in squamous cell lung
cancer (Engel et al., 1993) and neuroblastoma (Hailat et al.,
1991; Leone et al., 1993) disease-free survival as well as with
advanced (anaplastic) thyroid cancer stages (Zou et al.,
1993). However, other studies have shown that increased
Nm23 expression in lung (Higashiyama et al., 1992) and
thyroid (Farley et al., 1993) adenocarcinoma is not related to
lymph node or distant metastases.
Because of conflicing results, the role of Nrn23 expression
in colorectal cancer remains unclar. Colorectal cancer
patients with Nm23-Hl allelic deletion in their primary col-
orectal carcinoma develop more distant metastases than
those not harbouring this alteration (Cohn et al., 1991).
Recently, deletion in the coding sequence or alelic deletions
in Nm23-H1 were noted in 50% ofcolorectal cancer patients
with metastases to lymph nodes, lung or liver whereas none
was de in the non-metastatic lesions (Wang et al.,
1993). Furthermore, a somatic allelic loss of Nm23 in one
cancer patient and a homozygous deletion in a lymph node
metastases in another patient (Leone et al., 1991) indicate a
possible Metastases-suppressor role for Nm23 in colorectal
cancer. However, increased Nm23-Hl and Nm23-H2 RNA
in colorectal cancer relative to adjaent normal colonic
mucosa has been noted in both early and advanced stages,
with no relationship to metastatic activity (Haut et al., 1991;
Myeroff & Markowitz 1993).
The aim of this study was to determine, in a large series of
human primary colorectal cancer and liver metastases, the
utility of Nm23-H1 RNA and protein measurements in
primary colorectal canrs for assessing the presence of con-
comitant regional lymph node and distant metastases.
Materls and methob
Case material
Surgical specimens were obtained immediately after resection,
quick frozen in liquid nitrogen and stored at - 80-C until
procesd. Tumour specimens were obtained from the
tumour edge, thus avoiding a necrotic centre. Gross normal
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mucosa specimens were obtained from the surgical resection
margin by sharply dissecting the mucosa off the muscularis
propria.
Surgical specimens consisted of 59 primary colorectal
cancer and paired adjacent mucosa and five liver metastases
from colorectal cancer and paired normal liver including two
cases with synchronous liver metastases. None of the patients
had received previous radiation or chemotherapy.
Of the 59 primary colorectal cancer patients, 34 patients
(57.6%) were men and 25 (42.4%) were women. Their age
was 66.7 ± 10.8 (mean ± s.e.) with a range from 41 to 87
years. The tumours were located in the caecum (n = 5),
ascending colon (n = 14), transverse colon (3), descending
colon (n = 8), sigmoid colon (n = l1) and rectum (n = 18).
According to the International TNM staging system (Her-
manek & Sobin 1987), four (6.8%) of the lesions were TI, 11
(18.6%) were T2, 36 (61.0%) were T3 and eight (13.6%)
were T4. Histologically, there were four (7.2%) well-
differentiated, 43 (76.8%) moderately differentiated and nine
(16.0%) poorly differentiated adenocarcinomas. With regard
to metastases, no metastases were found in 26 patients
(44.1%), lymph node involvement was found in 16 patients
(27.1%) and distant metastases were found in 17 patients
(28.8%), including 12 patients with both lymph node and
distant metastases.
Northern blot analyses
Frozen tissue specimens were homogenised in 4M guan-
idinium thiocyanate followed by ultracentrifugation through
a caesuim chloride cushion, as previously described (Guillem
et al., 1990).
After isolation, 201tg of total cellular RNA per lane was
denatured in 50% formamide and 6% formaldehyde for
15 min at 65°C. Samples were then chilled on ice, and electro-
phoretically separated on a 1.0% agarose gel containing
6.8% formaldehyde. Fragments were transferred to a
Duralon-UV membrane (Stratagene) by capillary blotting in
10 x SSC for 16 h. Membranes were UV cross-linked with
120,000pJ cm-2 using a UV Strantalinker 1800 (Stratagene,
La Jolla, CA, USA). Blots were prehybridised (42-C, 50%
formamide, 10% dextran sulphate, 1% sodium dodecyl sul-
phate, 1 M sodium chloride and 100 zgml'- denatured
salmon sperm DNA) for 5 h and then hybridised overnight in
the same solution with 106 c.p.m. mr1 -nP-labelled probe.
Blots were washed to a final stringency of 65"C in 0.1 x SSC
and 0.1% SDS. Autoradiography was performed at - 80'C
with an intensifying screen. For rehybridisation, the bolts
were stripped by incubation in 0.1 x SSPE-0.5% SSC, 100lC
for 5 min. Blots were autoradiographed overnight to ensure
that all of the probe was removed before rehybridising with a
2-microglobulin probe.
Probes
The Nm23H-I probe is a 900 bp BamHI restriction endo-
nuclease DNA fragment of human Nm23-HI gene obtained
from the plasmid PNM23-HI. DNA fragments were purified
and recovered by low melting agarose gel electrophoresis
using GeneClean (BIO 101, La Jolla, Ca. USA). A human
2-microglobulin (P2-M) cDNA clone (Suggs et al., 1981) was
used as an internal control. The probes were radioactively
labelled with [32PJdeoxycytidine triphosphate according to the
method of Feinberg and Vogelstein (1983) using a random-
primed DNA labelling kit (Boehringer Mannheim
Biochemica).
Western blot analysis
Colorectal tumours and corresponding normal mucosa from
16 patients were subjected to Western blot analysis. The
tissue was thawed, weighed and homogenised in Tris buffer
(50 mm Tris-HCI, pH 7.5, containing 75 mm sodium chloride)
and centrifuged at 5,000 g for 20min. The supernatant was
stored at - 80°C.
Tumour and normal mucosa extracts (50gig) were electro-
phoresed on a 15% SDS-PAGE gel using a Minigel
apparatus (Bio-Rad, Richmond, CA, USA). Separated pro-
teins were transferred to nitrocellulose membranes (Amer-
sham, Bucks, UK) in Tris/glycine buffer (2.5 mM Tris,
192 mM glycine and 20% methanol) at 4°C and 100 V using a
Mini system. Non-specific binding sites were blocked for I h
at room temperature in 10 mM Tris buffer containing 150 mM
sodium chloride and 0.5% Tween 20 (TBS-T) with 4%
bovine serum albumin. The blots were incubated overnight at
4°C in a 1:500 dilution of a polyclonal antibody specific for
Nm23-Hl and then washed several times with TBS-T, fol-
lowed by an incubation step with horseradish peroxidase-
labelled anti-rabbit antibody (1:5,000 in TBS-T for 30 min at
room temperature). Then, after washing with TBS-T, an
enhanced chemiluminescence detection system (ECL, Amer-
sham) was used. For molecular weight determination, ECL
protein molecular weight marker and rainbow-coloured pro-
tein molecular weight marker (Amersham) were used.
Densitometric quantitation
Nm23-HI RNA and protein levels were quantitated by
measuring the intensities of the appropriate 'bands' in auto-
graphs using LKB XL laser densitometry (Pharmacia LKB
Biotechnology, Uppsala, Sweden).
The RNA results were expressed as the fold increase of a
0.8 kb Nm23 transcript in tumours compared with that in the
paired normal tissues, $3-M mRNA transcnrpts were used as
internal controls:
Tumour/normal (T/N) = TN.H13:T2-M/NN2HI:Np2-M
The Nm23-HI protein levels are expressed as the fold
increase in expression of the 17.0 and 18.5 kDa bands in
tumour relative to that measured in the corresponding adja-
cent normal mucosa.
Statistical anal!ses
The difference in Nm23-H1 between tumour and paired nor-
mal tissue was assessed by the paired t-test. The relationship
between Nm23-H1 and clinical variables in two groups was
analysed by Student's t-test. The difference in Nm23-HI in
multigroups was determined by analysis of variance
(ANOVA).
Reskts
Nm23-HJ RNA expression in prinary colorectal cancer
Total cellular RNA from 59 matched pairs of human col-
orectal cancer and adjacent normal mucosa were examined
for expression of Nm23-HI RNA by Northern blot hybridi-
sation. Figure 1 shows the expression of a 0.8 kb Nm23-Hl
transcript in total cellular RNA from tumour and matched
normal tissue. It suggests that Nm23-Hl mRNA levels were
elevated in colorectal cancer compared with those in normal
colon tissues. Densitometric analyses of the Northern blots
by comparison with normal mucosa indicated that Nm23-Hl
T NT NT NT NT NT NT N M L
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Fuwe 1 Northern blot analysis showing Nm23-HI mRNA level
in a tumour specimen (T), adjacent normal mucosa (N), liver
metastases (M) and adjacent normal liver (L) from a patient with
synchronous liver metastases. Nm23 expression was higher in
both primary tumour and liver metastases. Total RNA was hy-
bridised to Nm23-HI cDNA (top) and then rehybridised to P2-M
probe as a control (bottom).Nm23-Hl EXPRESSION IN COLORECTAL CANCER 1027
was overexpressed in all primary colorectal cancers when
compared with corresponding normal mucosa. The T/N fold
increase in Nm23-HI RNA ranged from 1.0 to 16.1 with a
mean ± s.e. of 4.3 ± 0.4. Nm23-Hl expression was
significantly increased in primary colorectal cancer relative to
adjacent normal mucosa (P<0.001).
Nm23-HJ RNA expression in liver metastasesfrom colorectal
cancer
High levels of Nm23-HI RNA expression were found in all
five liver metastases compared with corresponding normal
liver including two cases of synchronous liver metastases. As
shown in Figure 1, both primary tumour and liver metastases
from the same patient express greater Nm23-HI RNA than
normal tissues. The mean ± s.e. of TIN fold increase in
Nm23-Hl RNA expression was 5.1 ± 0.90. Nm23-Hl expres-
sion was significantly increased in tumour tissue compared
with adjacent normal liver (P<0.01).
Correlation ofNm23-HJ level and clinicopathological variables
The relationship between Nm23-H1 RNA overexpression in
primary colorectal cancer and clinicopathological parameters
is shown in Table I. No significant relationship was observed
between the T/N fold increase in Nm23-HI RNA and the
patient's sex (P = 0.67), age (P = 0.53), tumour location
(P = 0.99) or tumour differentiation (P = 0.99). Lower levels
of Nm23-HI RNA expression were found in small tumours.
The mean Nm23 RNA level was 2.6 ± 0.5 for tumours less
than 3.0 cm and 4.6 ± 0.5 for those equal to or greater than
3.0 cm. This difference was statistically significant
(P = 0.05).
Relationship bet%,een Nm23-HJ expression and local tumour
invasion
The T/N fold increase in Nm23-Hl RNA for TI, T2, T3 and
T4 lesions was 1.9 ± 0.3; 4.1 ± 0.6; 4.1 ± 0.5 and 6.4 ± 1.6
respectively. Although there appeared to be a trend between
increasing relative Nm23-Hl RNA overexpression and degree
of bowel wall penetration, irrespective of lymph node and
distant metastases status, statistical significance (P<0.01)
was achieved only when superficial lesions (TI) were com-
pared with advanced ones (T2, T3 and T4).
Relationship between Nm23-HJ RNA level and colorectal
cancer metastases
Figure 2 displays the distribution of Nm23H-1 RNA level in
primary colorectal cancer according to Dukes' stage. No
distinct trend was observed between Nm23-HI RNA expres-
sion and Dukes' stage. Attempts were made to correlate the
expression of Nm23-Hl RNA with tumour metastatic para-
meters. The T/N fold increase of Nm23-HI RNA expression
in the negative and positive lymph nodes metastases groups
was 4.3 ± 0.6 and 4.2 ± 0.6 respectively. Similarly, no rela-
tionship was noted between the levels of Nm23-HI RNA in
primary colorectal cancers and the presence of distant metas-
tases. The T/N fold-increase in Nm23-Hl RNA was 4.3 ± 0.6
and 4.1 ± 0.6 for 42 colorectal cancer patients without dis-
tant metastases and 17 patients with synchronous metastases
Table I Correlation between Nm23-H1 overexpression in primary colorectal cancer
and clinicopathological parameters
No. of Nm23-HJ t-test
Parameter cases (%) Mean s.e. Range F-tesr P-value
Sex
Female 25 (57.6) 4.0 0.5 1.0-9.6
Male 34 (42.4) 4.4 0.6 1.2-16.1 0.46 0.67
Age (years)
<60 13 (22.0) 4.1 0.5 1.5-8.4
60-70 23 (39.0) 3.8 0.5 1.2-9.4
> 70 23 (39.0) 4.8 0.9 1.0-16.1 0.64 0.53
Tumour location
Right 22 (37.3) 4.2 0.6 1.2-16.1
Left 19 (32.2) 4.3 0.7 1.0-11.0
Rectum 18 (30.5) 4.2 0.8 1.3-12.7 0.007 0.99
Tumour size (cm) (maximum)
<3.0 10 (16.9) 2.6 0.4 1.2-5.2
> 3.0 49 (83.1) 4.6 0.5 1.0-16.1 2.23 0.05
Tumour differentiation
Good 7 (11.9) 4.0 1.3 1.3-9.6
Moderate 44 (74.6) 4.3 0.5 1.0-16.1
Poor 8 (13.5) 4.1 0.8 1.2-8.8 0.007 0.99
T stage
TI 4 (6.8) 1.9 0.3 1.3-2.8
T2 11 (18.6) 4.1 0.6 1.2-9.0
T3 36 (61.0) 4.1 0.5 1.2-14.0
T4 8 (13.6) 6.4 1.6 1.0-16.1 1.55 0.20
Lymph node metastases
NO 31 (52.5) 4.3 0.6 1.0-16.1
NJ -3 28 (47.5) 4.2 0.6 1.2-14.0 0.17 0.87
Distant metastases
MO 42 (71.2) 4.1 0.5 1.0-16.1
Ml 17 (28.8) 4.3 0.6 1.3-9.6 0.27 0.79
Dukes' stage
A 13 (22.0) 3.2 0.6 1.2-9.0
B 14 (23.7) 4.7 1.1 1.0-16.1
C 15 (25.5) 5.5 1.1 1.2- 14.0
D 17 (28.8) 4.3 0.6 1.3-9.6 1.11 0.35
t-test for comparison of two groups, F-test for comparison of more than two
groups.1028 Z.S. ZENG et al.
(15 patients with liver metastases, one with lung metastases
and one with peritoneal metastases).
Nm23-hJ protein levels in primary colorectal cancer
The expression of Nm23-H1 protein detected by Western
blot analysis is shown in Figure 3. Two bands, 17.0 and
18.5 kDa, were identified by anti-Nm23-Hl polyclonal
antibody. In 16 colorectal cancer patients, 17.0 kDa and
18.5 kDa Nm23-HI protein expression was increased in
tumour tissue compared with normal adjacent mucosa in
81.3% and 87.5% of patients respectively (Table II). The
mean tumour to normal mucosa fold increase was
2.66 ± 0.46 (mean ± s.e.) (range 0.7-7.4) (P<0.001) and
2.40 + 0.32 (range 0.8-5.7) (P<0.001) in 17.0 and 18.5 kDa
bands. According to Dukes' A, B, C and D stage, the mean
Nm23-HI levels was 1.80 ± 1.10, 2.93 ± 0.94, 1.98 ± 0.49,
3.48 1.12 for 17.0 kDa and 1.20 ± 0.20, 2.48 0.70,
2.54 ± 0.39, 2.68 ± 0.78 for 18.5 kDa respectively (Figure 4).
Neither the 17.0 kDa (P = 0.57) nor the 18.0 kDa (P = 0.60)
Nm23-HI band differed significantly with advancing Dukes'
stage.
A B C
Dukes' stage
D
Frgwe 2 Levels of Nm23-HI mRNA in primary colorectal
cancer based on Dukes' stage. Each data point represents the
level of Nm23-HI RNA expression in patient's tumour as deter-
mined by scanning densitometry of a Northern blot as described
in the Matenral and methods section.
kDa
30-
21.5-
14.3-
Decreased expression of the Nm23-HI gene has been
associated with metastatic potential in experimental model
systems (Steeg et al., 1988a), human breast cancer (Bevilac-
qua et al., 1989; Barnes et al., 1991; Hennessey et al., 1991;
Tokunaga et al., 1993) hepatocellular carcinoma (Nakayama
et al., 1992) and melanoma (Florenes et al., 1992), consistent
with a possible tumour metastases-suppressor role for Nm23
in these cancers. In contast, increased expression ofNm23-Hl
has been associated with worsening prognosis in thyroid
cancer (Farley et al., 1993; Zou et al., 1993), squamous lung
cancer (Engel et al., 1993) and neuroblastoma (Hailat et al.,
1991). In colorectal cancer, although allelic loss ofNm23 has
been assoaated with icreased metastatic potential (Cohn et
al., 1991), Nm23-HI and Nm23-H2 expression is elevated in
most colorectal cancers examined (Haut et al., 1991; Myeroff
& Markowitz, 1993). Furthermore, in small series ofpatients,
the extent of Nm23 expression was found to be similar
T N T N T N T N
0
CD
~0
CD
,0
4- z
4- P-
Figwe 3 Western blot analysis of Nm23-HI in colorectal cancer.
Tumour (T) and normal mucosa (N) extracts (50 zg) from each
patient were separated by 15% SDS-PAGE and transferred to
nitrocellulose membranes. The membranes were incubated with
an anti-Nm23-HI polyclonal antibody and visualised as described
in the Material and methods section. The position of Nm23-HI is
indicated by arrows. The top arrow indicates the 18.5 kDa band
and the bottom arrow indicates the 17.01kDa band.
Dukes' stage
Fugwe 4 Correlation between Nm23-Hl protein levels and
Dukes' stage in colorectal cancer. Data are expressed as
mean ± s.e. of tumour/normal mucosa fold increase. No
significnt differences were observed between Dukes' stage and
Nm23-HI protein levels in both 17.0 ([L]) (P=0.57) and
18.5kDa (M) (P=0.60) bands.
Table II Nm23-HI protein levels in primary colorectal cancer
No of Age Tumour Dukes' Nm23-HJ
cases (Years) Sex Differentiation stage 17.0 kDa 18.5 kDa
1 72 F Moderately A 2.9 1.4
2 64 M Moderately A 0.7 1.0
3 62 F Moderately B 0.8 0.8
4 41 F Good B 3.9 2.6
5 70 F Moderately B 5.0 4.2
6 49 F Moderately B 2.0 2.3
7 62 M Moderately C 0.9 3.4
8 69 F Moderately C 2.5 1.6
9 -76 M Moderately C 3.6 1.6
10 72 M Moderately C 1.2 3.0
11 87 F Poorly C 1.7 3.1
12 61 M Poorly D 1.6 1.3
13 73 M Poorly D 4.3 2.3
14 71 M Moderately D 1.2 5.7
15 60 M Moderately D 7.4 2.4
16 68 M Moderately D 2.9 1.7
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between metastatic and non-metastatic lesions (Haut et al..
1991).
More recently, an adverse association between Nm23-H1
mRNA and protein expression in colorectal cancer has been
reported (Ayhan et al., 1993; Yamaguchi et al., 1993). How-
ever, a close statistical analysis of the results reported by
Yamaguchi et al. does not support their conclusion. In that
study, Nm23-H1 RNA expression was lower in five patients
(1.55 ± 0.63) with colorectal cancer and liver metastases than
in 16 patients (2.45 ± 1.02) without liver metastases
(P<0.05). However, using their data, we could not obtain
signfcance using Student's t-test (t = 1.85, P = 0.085, two-
tailed). Similarly, analysis of their published protein data did
not reveal any statistical significance: the chi-square value
was 0.7 (P = 0.40) and P-values obtained by the Fisher's
exact test were 0.367 (one-tailed) and 0.581 (two-tailed).
Our results demonstrate, in a large series of colorectal
cancer patients, that Nm23-HI RNA was significantly in-
creased at all stages of primary colorectal cancer relative to
adjacent normal mucosa. In addition, we demonstrate for the
first time that liver metastases also express more Nm23-H1
RNA than normal liver. In agreement with overexpression of
Nm23-H1 RNA in colorectal cancer, Nm23-H1 protein levels
were also significantly increased in tumour tissue compared
with normal adjacent mucosa. However, there were no sig-
nificant differences between Dukes' stage based on metastases
status and Nm23-Hl expression in both RNA and protein
levels. High Nm23-H1 RNA levels were significantly cor-
related with locally advanced lesions (T2-T4) and more large
tumours than small tumours expressed high levels of Nm23-
H1 mRNA. These results suggest that in colorectal cancer
the Nm23H-1 gene may play an important role in local
disease progression rather than in metastases suppression.
Differences in the relationship between Nm23 expression
and disease progression in different tumours suggest possible
tissue-specific functions. Certainly, the bulk of the evidence
would suggest a probable tumour anti-metastatic role for
Nm23 in melanoma, the tumour cell line from which Nm23
was isolated (Florenes et al., 1992) as well as breast cancer
(Belivacqua et al., 1989; Barnes et al., 1991; Hennesy et al.,
1991; Hirayama et al., 1991; Royds et al., 1993) and
hepatocellular carcinoma (Nakayama et al., 1992). Similarly.
the frequent occurrence of Nm23 genetic alterations (loss of
heterozygosity or deletion in coding sequences) in metastatic
colorectal cancers would suggest a possible tumour
metastases-suppressor role for Nm23 in colorectal cancer as
well. However, the uniform overexpression of Nm23-H1
RNA observed in both metastatic and non-metastatic col-
orectal cancer as well as in metastatic sites themselves is
inconsistent with Nm23-H1 being a colorectal cancer meta-
stases suppressor. One proposed hypothesis is that a gene
linked to Nm23-Hl and therefore deleted along with the
Nm23-Hl allele may actually be a colorectal cancer meta-
stases suppressor (Myeroff & Markowitz, 1993). An alterna-
tive hypothesis is that mutations in the Nm23 gene produce a
protein, functionally distinct from the wild type, that
facilitates growth and metastases.
The Nm23-HI and Nm23-H2 genes are identical to the
primary structures of human NDP kinase A and B respec-
tively (Gilles et al., 1991). Previous reports have shown that
expression of Nm23 and NDP kinase (NDPK) (Golden et
al., 1992) correlates with proliferation of lymphoid cells
(Keim et al., 1992). The observation that a differentiation-
inhibiting factor in mouse myeloid leukaemic cell lines is the
murine homologue of Nm23-H2 (Okabe-Kado et al., 1992)
suggests that Nm23 may also be involved in cellular
differentiation. Most recently, it has been demonstrated that
the Nm23 protein may be a transcriptional factor for c-myc
expression (Postel et al., 1993). Although no relationship has
been established between c-myc expression and metastases,
increased c-myc expression is frequently noted in colorectal
cancer (Erisman et al., 1985; Guillem et al., 1990) and in
some systems is associated with decreased cellular
differentiation (Spencer & Groudine, 1991). However, in our
series of colorectal cancer specimens, we did not observe any
relationship between Nm23 RNA expression and degree of
differentiation of the primary colorectal cancer.
Although originally linked to tumour metastases suppres-
sion, it is becoming evident that Nm23 may have numerous
other functions, some of which may be tissue specific. Since
Nm23-Hl RNA expression is associated with increasing colo-
rectal cancer size and extent of local bowel invasion, Nm23-
H1 RNA expression may be associated with local aggressive
behaviour. However, Nm23-HI RNA overexpression in
primary colorectal cancers does not appear to correlate with
synchronous regional or distant metastases. Further studies
are needed to determine Nm23-H2 expression in colorectal
cancer as well as the overall relationship between Nm23 and
other proliferation-differentiation-related genes in colorectal
cancer.
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